📣 VC round data is live. Check it out!
- Public Comps
- Betta Pharmaceuticals
Betta Pharmaceuticals Valuation Multiples
Discover Betta Pharmaceuticals' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Hypera, Beam Therapeutics, BioArctic, Jiangsu Nhwa and more.
Betta Pharmaceuticals Overview
About Betta Pharmaceuticals
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Founded
2003
HQ

Employees
N/A
Website
Financials (LTM)
EV
$3B
Valuation Multiples
Start free trialBetta Pharmaceuticals Financials
Betta Pharmaceuticals reported last 12-month revenue of $580M and EBITDA of $188M.
In the same LTM period, Betta Pharmaceuticals generated $188M in EBITDA and $75M in net income.
Revenue (LTM)
Betta Pharmaceuticals P&L
In the most recent fiscal year, Betta Pharmaceuticals reported revenue of $534M and EBITDA of $159M.
Betta Pharmaceuticals is profitable as of last fiscal year, with gross margin of 80%, EBITDA margin of 30%, and net margin of 8%.
Financial data powered by Morningstar, Inc.
Betta Pharmaceuticals Stock Performance
Betta Pharmaceuticals has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Betta Pharmaceuticals' stock price is $7.14.
Betta Pharmaceuticals share price decreased by 8.1% in the last 30 days, and by 15.1% in the last year.
Betta Pharmaceuticals has an EPS (earnings per share) of $0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -5.6% | -8.1% | 11.7% | -15.1% | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBetta Pharmaceuticals Valuation Multiples
Betta Pharmaceuticals trades at 5.7x EV/Revenue multiple, and 17.6x EV/EBITDA.
EV / Revenue (LTM)
Betta Pharmaceuticals Financial Valuation Multiples
As of June 3, 2026, Betta Pharmaceuticals has market cap of $3B and EV of $3B.
Betta Pharmaceuticals has a P/E ratio of 40.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Betta Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Betta Pharmaceuticals Margins & Growth Rates
Betta Pharmaceuticals grew revenue by 22% and EBITDA by 43% in the last fiscal year.
In the most recent fiscal year, Betta Pharmaceuticals reported gross margin of 80%, EBITDA margin of 30%, and net margin of 8%.
Betta Pharmaceuticals Margins
Betta Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Betta Pharmaceuticals Operational KPIs
Betta Pharmaceuticals' Rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Betta Pharmaceuticals' Rule of X is 90% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Betta Pharmaceuticals Competitors
Betta Pharmaceuticals competitors include Hypera, Beam Therapeutics, BioArctic, Jiangsu Nhwa, InnoCare Pharma, BB Biotech, Jilin Aodong, Denali Therapeutics, Jamjoom Pharma and Arcus Biosciences.
Most Betta Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.8x | 2.6x | 9.5x | 8.8x | |||
| 14.4x | 18.2x | (5.6x) | (4.9x) | |||
| 12.6x | 15.6x | 20.5x | 30.8x | |||
| 2.8x | 2.7x | 12.0x | 13.0x | |||
| 14.4x | 6.3x | (46.6x) | 36.6x | |||
| 4.0x | - | - | - | |||
| 8.6x | - | 7.5x | - | |||
| - | 104.6x | (4.1x) | (4.0x) | |||
This data is available for Pro users. Sign up to see all Betta Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
Investments by Betta Pharmaceuticals
Betta Pharmaceuticals has invested in 6 companies to date.
Latest investment by Betta Pharmaceuticals was on January 9th 2026. Betta Pharmaceuticals invested in Zhixing Pharmaceutical in their $7M Secondary - private round (EV/Revenue multiple available to Pro users).
Latest Investments by Betta Pharmaceuticals
| Description | Zhixing Pharmaceutical is a company specializing in research, development, and production of high-end inhaled formulations for respiratory therapies using advanced drug delivery technologies. | Reprogenix is a biotechnology company advancing stem cell therapies starting with type 1 diabetes treatment. The firm develops allogeneic mesenchymal stem cell products to restore insulin production and expand applications to autoimmune and degenerative diseases. Headquartered in the United States, Reprogenix conducts preclinical studies and clinical trials targeting beta cell regeneration through proprietary cell manufacturing processes. | E-nitiate Biopharmaceuticals is a China-based developer of therapies for autoimmune diseases through independent R&D and collaborations. The company advances drug candidates targeting rheumatoid arthritis, lupus, and inflammatory conditions. | Capio Biosciences is a biotechnology firm developing the CapioCyte platform for circulating tumor cell capture from whole blood samples. The technology employs biomimetic rolling and dendrimer-based multivalent binding to achieve higher sensitivity than competing methods, enabling downstream analyses like FISH, RNA-Seq, and NGS for oncology research. Capio Biosciences targets applications in cancer diagnostics and personalized treatment monitoring. | |
| HQ Country | |||||
| HQ City | - | Hangzhou | Hangzhou | Madison, WI | |
| Deal Date | 9 Jan 2026 | 4 Nov 2024 | 31 Aug 2022 | 5 Jan 2017 | |
| Round | Secondary - private | Series A | Angel | Series A | |
| Raised | $7M | $14M | $3M | $3M | |
| Investors | Betta Pharmaceuticals | BeiChen Venture Capital Management; Betta Pharmaceuticals; China Venture Capital; Lenovo Capital and Incubator Group (LCIG); Lotus Lake Ventures | Betta Pharmaceuticals | Betta Pharmaceuticals | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Betta Pharmaceuticals investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Betta Pharmaceuticals
| When was Betta Pharmaceuticals founded? | Betta Pharmaceuticals was founded in 2003. |
| Where is Betta Pharmaceuticals headquartered? | Betta Pharmaceuticals is headquartered in China. |
| Who is the CEO of Betta Pharmaceuticals? | Betta Pharmaceuticals' CEO is Lieming Ding. |
| Is Betta Pharmaceuticals publicly listed? | Yes, Betta Pharmaceuticals is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Betta Pharmaceuticals? | Betta Pharmaceuticals trades under 300558 ticker. |
| When did Betta Pharmaceuticals go public? | Betta Pharmaceuticals went public in 2016. |
| Who are competitors of Betta Pharmaceuticals? | Betta Pharmaceuticals main competitors include Hypera, Beam Therapeutics, BioArctic, Jiangsu Nhwa, InnoCare Pharma, BB Biotech, Jilin Aodong, Denali Therapeutics, Jamjoom Pharma, Arcus Biosciences. |
| What is the current market cap of Betta Pharmaceuticals? | Betta Pharmaceuticals' current market cap is $3B. |
| What is the current revenue of Betta Pharmaceuticals? | Betta Pharmaceuticals' last 12 months revenue is $580M. |
| What is the current revenue growth of Betta Pharmaceuticals? | Betta Pharmaceuticals revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Betta Pharmaceuticals? | Current revenue multiple of Betta Pharmaceuticals is 5.7x. |
| What is the current EBITDA of Betta Pharmaceuticals? | Betta Pharmaceuticals' last 12 months EBITDA is $188M. |
| What is Betta Pharmaceuticals' EBITDA margin? | Betta Pharmaceuticals' last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Betta Pharmaceuticals? | Current EBITDA multiple of Betta Pharmaceuticals is 17.6x. |
| How many companies Betta Pharmaceuticals has acquired to date? | Betta Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Betta Pharmaceuticals has invested to date? | As of June 2026, Betta Pharmaceuticals has invested in 6 companies. |
See public comps similar to Betta Pharmaceuticals
Lists including Betta Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

